592 related articles for article (PubMed ID: 27485081)
1. Perspectives of ofatumumab as CD20 targeted therapy in rheumatoid arthritis and other autoimmune diseases.
Pers YM; Jorgensen C
Immunotherapy; 2016 Sep; 8(9):1091-6. PubMed ID: 27485081
[TBL] [Abstract][Full Text] [Related]
2. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies.
Robak T; Robak E
BioDrugs; 2011 Feb; 25(1):13-25. PubMed ID: 21090841
[TBL] [Abstract][Full Text] [Related]
3. Optimising B-cell depletion in autoimmune disease: is obinutuzumab the answer?
Reddy V; Dahal LN; Cragg MS; Leandro M
Drug Discov Today; 2016 Aug; 21(8):1330-8. PubMed ID: 27343722
[TBL] [Abstract][Full Text] [Related]
4. Current status on B-cell depletion therapy in autoimmune diseases other than rheumatoid arthritis.
Dörner T; Isenberg D; Jayne D; Wiendl H; Zillikens D; Burmester G;
Autoimmun Rev; 2009 Dec; 9(2):82-9. PubMed ID: 19716441
[TBL] [Abstract][Full Text] [Related]
5. [B cell targeting therapy using the anti-CD20 antibody in autoimmune diseases].
Tanaka Y
Yakugaku Zasshi; 2009 Jun; 129(6):675-9. PubMed ID: 19483410
[TBL] [Abstract][Full Text] [Related]
6. [Research progress on B cell surface molecules targeted therapy in rheumatoid arthritis].
Di W; Chang Y; Wu YJ; Wei W
Sheng Li Ke Xue Jin Zhan; 2011 Jun; 42(3):175-80. PubMed ID: 21932514
[TBL] [Abstract][Full Text] [Related]
7. Long term treatment of rheumatoid arthritis with rituximab.
Caporali R; Caprioli M; Bobbio-Pallavicini F; Bugatti S; Montecucco C
Autoimmun Rev; 2009 Jun; 8(7):591-4. PubMed ID: 19393205
[TBL] [Abstract][Full Text] [Related]
8. Ocrelizumab: a step forward in the evolution of B-cell therapy.
Kausar F; Mustafa K; Sweis G; Sawaqed R; Alawneh K; Salloum R; Badaracco M; Niewold TB; Sweiss NJ
Expert Opin Biol Ther; 2009 Jul; 9(7):889-95. PubMed ID: 19463076
[TBL] [Abstract][Full Text] [Related]
9. B cell-directed therapy in rheumatoid arthritis--clinical experience.
Panayi GS
J Rheumatol Suppl; 2005 Feb; 73():19-24; discussion 29-30. PubMed ID: 15693112
[TBL] [Abstract][Full Text] [Related]
10. B lymphocyte depletion in rheumatoid arthritis: targeting of CD20.
Edwards JC; Leandro MJ; Cambridge G
Curr Dir Autoimmun; 2005; 8():175-92. PubMed ID: 15564721
[TBL] [Abstract][Full Text] [Related]
11. Treatment of inflammatory immunologic disease 4. B cell targeting therapy using the anti-CD20 antibody rituximab in inflammatory autoimmune diseases.
Tanaka Y
Intern Med; 2007; 46(16):1313-5. PubMed ID: 17704614
[No Abstract] [Full Text] [Related]
12. [Targeting CD20 in rheumatoid arthritis].
Saito K; Tanaka Y
Nihon Rinsho; 2007 Jul; 65(7):1243-9. PubMed ID: 17642239
[TBL] [Abstract][Full Text] [Related]
13. B cell-directed therapies in multiple sclerosis.
Gasperi C; Stüve O; Hemmer B
Neurodegener Dis Manag; 2016; 6(1):37-47. PubMed ID: 26782316
[TBL] [Abstract][Full Text] [Related]
14. Ofatumumab, a second-generation anti-CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disorders.
Castillo J; Milani C; Mendez-Allwood D
Expert Opin Investig Drugs; 2009 Apr; 18(4):491-500. PubMed ID: 19335277
[TBL] [Abstract][Full Text] [Related]
15. Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia: from uncertainties to promises.
Bagacean C; Zdrenghea M; Tempescul A; Cristea V; Renaudineau Y
Immunotherapy; 2016 May; 8(5):569-81. PubMed ID: 27140410
[TBL] [Abstract][Full Text] [Related]
16. B cell depletion in the treatment of multiple sclerosis.
Myhr KM; Torkildsen Ø; Lossius A; Bø L; Holmøy T
Expert Opin Biol Ther; 2019 Mar; 19(3):261-271. PubMed ID: 30632834
[TBL] [Abstract][Full Text] [Related]
17. B-cell: a logical target for treatment of rheumatoid arthritis.
Youinou P; Jamin C; Saraux A
Clin Exp Rheumatol; 2007; 25(2):318-28. PubMed ID: 17543163
[TBL] [Abstract][Full Text] [Related]
18. COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases.
Baker D; Roberts CAK; Pryce G; Kang AS; Marta M; Reyes S; Schmierer K; Giovannoni G; Amor S
Clin Exp Immunol; 2020 Nov; 202(2):149-161. PubMed ID: 32671831
[TBL] [Abstract][Full Text] [Related]
19. B cells as a therapeutic target in autoimmune diseases other than rheumatoid arthritis.
Looney RJ
Rheumatology (Oxford); 2005 May; 44 Suppl 2():ii13-ii17. PubMed ID: 15851522
[TBL] [Abstract][Full Text] [Related]
20. [B cells as key contributors in determining the level of immune responses -B-cell-targeted therapy in patients with autoimmune diseases].
Kondo S; Akashi T; Katsuta H; Iwakiri R; Anzai K; Nagafuchi S; Niho Y; Harada M
Fukuoka Igaku Zasshi; 2005 Apr; 96(4):86-92. PubMed ID: 15991605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
